ArticleGels (Basel, Switzerland)2023
Synthesis and Degradation Properties of Sericin/PVA Hydrogels.
Article in Gels (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 32 citations in OpenAlex.
- Dual-Responsive Hydrogels Integrate Bioelectrical Stimulation and Piezo-Photocatalysis for Regenerative Treatment of Infected Wounds.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Multifunctional Silk Fibroin Hydrogel with Antibacterial and Regenerative Properties for Accelerated Wound Healing.Gels (Basel, Switzerland) · 2026Article
- A Glucose-Responsive CeO₂@GOx Nanozyme Embedded in Chitosan/PVA Hydrogel for Accelerated Diabetic Wound Healing: from Molecular Simulations toNanotheranostics · 2026Article
- Silk sericin and its biomedical applications: extraction methods, genetic insights (Ser1-Ser6), and developments of multifunctional biomaterials for tissue regeneration.Frontiers in bioengineering and biotechnology · 2026Review
- Propolis enhanced sodium alginate hydrogel enriched with copper doped mesoporous bioactive glass nanoparticles for advanced burn care applications.Biotechnology letters · 2025Article
- Evaluation of Sericin/Polyvinyl Alcohol Mixtures for Developing Porous and Stable Structures.Biomimetics (Basel, Switzerland) · 2025Article
- Sericin coats of silk fibres, a degumming waste or future material?Materials today. Bio · 2024Article
- Article
- Enhancing Wound Healing: A Comprehensive Review of Sericin andMaterials (Basel, Switzerland) · 2024Review
- Article
- Eco-Friendly Production of Polyvinyl Alcohol/Carboxymethyl Cellulose Wound Healing Dressing Containing Sericin.Gels (Basel, Switzerland) · 2024Article
- Melatonin/Sericin Wound Healing Patches: Implications for Melanoma Therapy.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
One method of treating diabetic foot ulcers, mainly superficial and deep ulcers, is using a wound dressing in the form of a hydrogel. Sericin derived from silkworm cocoons is a promising hydrogel material candidate because it has anti-inflammatory properties and stimulates collagen production. Sericin was combined with PVA to increase the stability of the resulting hydrogel. Sericin/PVA hydrogel was prepared using the freeze-thawing method with variations in the solution concentration and volume ratio of PVA and sericin. Sericin was successfully extracted using an autoclave method. The FTIR results confirmed that sericin extracted from the cocoon had a dominant secondary structure in the form of a β-sheet. Hydrogel with a concentration of 4% with a 1:1 ratio of PVA and sericin showed good stability and resulted in a hydrogel with characteristics that combine PVA and sericin. The resulting hydrogel had an average pore size range of 24-191 µm and a porosity range of 70-85%, which meets the requirements for wound dressings. Through degradation testing in PBS solution, it was found that the sericin/PVA hydrogel experienced degradation of 60-75% after 672 h of testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.